Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05067387 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Oral THC and CBD in Men and Women
A Phase 1 study, sponsored by University of California, Los Angeles.
- Not yet
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT05067387: Clinical Trial Phase 1 study, sponsored by University of California, Los Angeles.
NCT05067387 is a Phase 1 study that has not yet begun recruiting, run by University of California, Los Angeles. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05067387, a Phase 1 study, has not yet begun recruiting, sponsored by University of California, Los Angeles.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.
Primary Outcome
Average and peak subjective ratings of drug effects associated with abuse liability as measured using visual analogue scales (VAS; 1-100mm).
Interventions
- DRUG Placebo
- DRUG THC
- DRUG CBD
- DRUG THC + CBD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2028-06-15 |
| Phase | Phase 1 |
What is known before NCT05067387 opens enrollment
NCT05067387 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05067387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05067387 about?
NCT05067387 is a clinical study titled "Evaluation of Oral THC and CBD in Men and Women". The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.
What is the current status of trial NCT05067387?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2026-07-15. Estimated completion is 2028-06-15.
What interventions are being tested in trial NCT05067387?
The interventions under investigation include: Placebo (DRUG), THC (DRUG), CBD (DRUG), THC + CBD (DRUG).
Who is sponsoring clinical trial NCT05067387?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05067387's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI